BLSM · Insider Trading
BlossomHill Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by BLSM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Carl L Gordon | Director | MIXED | +2,714,279 | +$10.00M |
| 2026-08-12 | ORBIMED ADVISORS LLC | Director | MIXED | +2,714,279 | +$10.00M |
| 2026-08-10 | Yishan Li | Executive Chairman | C | +1,838,896 | — |
| 2026-08-10 | Cormorant Asset Management, LP | 10%+ Owner | MIXED | +3,614,034 | +$5.00M |
| 2026-08-10 | Vincent Paul Liptak | General Counsel | MIXED | +27,387 | +$74.70K |
| 2026-08-10 | Jason A Keyes | Chief Financial Officer | Buy | +700 | +$11.20K |
| 2026-08-10 | Jingrong Jean Cui | President and CEO | C | +1,838,896 | — |
| 2026-08-10 | John P. Schmid | Director | Buy | +6,000 | +$96.00K |
| 2026-08-10 | Geoffrey Raymond Oxnard | Chief Medical Officer | A | +61,783 deriv. | — |
| 2026-08-10 | Carl L Gordon | Director | A | +23,904 deriv. | — |
| 2026-08-10 | Sundeep Agrawal | Director | C | +578,524 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Cormorant Asset Management, LP | 10%+ Owner | 3,614,034 | $44.74M |
| Cormorant Private Healthcare Fund V LP | 10%+ Owner | 3,301,534 | $40.87M |
| Yishan Li | Executive Chairman | 2,781,238 | $34.43M |
| Jingrong Jean Cui | President and CEO | 2,667,803 | $33.03M |
| Carl L Gordon | Director | 2,089,279 | $25.87M |
| ORBIMED ADVISORS LLC | Director | 1,039,996 | $12.88M |
| Sundeep Agrawal | Director | 578,524 | $7.16M |
| Vincent Paul Liptak | General Counsel | 134,099 | $1.66M |
| John P. Schmid | Director | 6,000 | $74.28K |
| Jason A Keyes | Chief Financial Officer | 700 | $8.67K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BLSM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.